Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16099428
Hiratani K, et al. (2005) Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of IRS-1. Biochem Biophys Res Commun 335, 836-42 16099428
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S307-p - IRS1 (human)
Modsite: TRRsRtEsItAtsPA SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): S307‑p, IRS1 (mouse): S302‑p, IRS1 (rat): S302‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout]
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
SP600125 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
anisomycin increase
SP600125 anisomycin inhibit treatment-induced increase
rapamycin anisomycin inhibit treatment-induced increase

S636-p - IRS1 (human)
Modsite: sGDyMPMsPKsVSAP SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): S636‑p, IRS1 (mouse): S632‑p, IRS1 (rat): S632‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout]
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
SP600125 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
anisomycin increase
SP600125 anisomycin inhibit treatment-induced increase
rapamycin anisomycin inhibit treatment-induced increase

S639-p - IRS1 (human)
Modsite: yMPMsPKsVSAPQQI SwissProt Entrez-Gene
Orthologous residues
IRS1 (human): S639‑p, IRS1 (mouse): S635‑p, IRS1 (rat): S635‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout]
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
SP600125 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
anisomycin increase
SP600125 anisomycin inhibit treatment-induced increase
rapamycin anisomycin inhibit treatment-induced increase

S63-p - Jun (human)
Modsite: kNsDLLtsPDVGLLk SwissProt Entrez-Gene
Orthologous residues
Jun (human): S63‑p, Jun (mouse): S63‑p, Jun (rat): S63‑p, Jun (cow): S63‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout]
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
SP600125 insulin no effect upon treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
anisomycin increase
SP600125 anisomycin inhibit treatment-induced increase
rapamycin anisomycin no effect upon treatment-induced increase

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody
Relevant cell lines - cell types - tissues:  3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout]
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
SP600125 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
anisomycin increase
SP600125 anisomycin inhibit treatment-induced increase
rapamycin anisomycin inhibit treatment-induced increase